The results showed that the effects of TDZD-8 treatment on the pathological characteristics of AD, such as APP metabolism and Tau phosphorylation, were consistent with those of NAP1L5 overexpression (Figures 5E–L). Here, NAP1L5 is linked to Alzheimer disease.